Methodist Estabrook Cancer Center Awarded FACT Accreditation
Methodist Estabrook Cancer Center has received internationally-recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center.
By demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration, Methodist has earned FACT Accreditation for its stem cell program.
This marks the second time Methodist Estabrook Cancer Center has earned the FACT accreditation, having also received the recognition in 2014.
FACT is an internationally-recognized accrediting body for hospitals and medical institutions offering stem cell transplant, and indicates the accredited institution has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release.
“We endeavored to achieve accreditation for our organization because FACT accreditation has evolved into an all-but-necessary qualification to be accepted and competitive in the field of cellular therapy,” said Patty Bauer, oncology service executive at Methodist Estabrook Cancer Center. “We believe FACT Accreditation will make patients aware that our facility strives to achieve the highest quality care for cellular therapy treatment programs.”
FACT-JACIE Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy transplantation. Methodist has been found to be in compliance with these rigorous Standards as well as governmental regulations.
“We are pleased that Methodist has met the requirements of the Foundation and has been granted accreditation for their stem cell program,” said Dr. Phyllis Warkentin, FACT’s Chief Medical Officer.
Accreditation is attained through evaluation of submitted documentation and on-site inspection to determine if an organization is in compliance with current FACT standards and the United States Food and Drug Administration’s current rules for Good Tissue Practice. FACT Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy.